Exhaled breath condensate: a new method for lung disease diagnosis

Author(s):  
Ivana Čepelak ◽  
Slavica Dodig
10.2196/23831 ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. e23831
Author(s):  
Lauren Fox ◽  
Jessica Gates ◽  
Ruth De Vos ◽  
Laura Wiffen ◽  
Alexander Hicks ◽  
...  

Background More than 7% of the world’s population is living with a chronic respiratory condition. In the United Kingdom, lung disease affects approximately 1 in 5 people, resulting in over 700,000 hospital admissions each year. People with respiratory conditions have several symptoms and can require multiple health care visits and investigations before a diagnosis is made. The tests available can be difficult to perform, especially if a person is symptomatic, leading to poor quality results. A new, easy-to-perform, point-of-care test that can be performed in any health care setting and that can differentiate between various respiratory conditions would have a significant, beneficial impact on the ability to diagnose respiratory diseases. Objective The objective of this study is to use a new handheld device (Inflammacheck) in different respiratory conditions to measure the exhaled breath condensate hydrogen peroxide (EBC H2O2) and compare these results with those of healthy controls and with each other. This study also aims to determine whether the device can measure other parameters, including breath humidity, breath temperature, breath flow dynamics, and end tidal carbon dioxide. Methods We will perform a single-visit, cross-sectional observational study of EBC H2O2 levels, as measured by Inflammacheck, in people with respiratory disease and volunteers with no known lung disease. Participants with a confirmed diagnosis of asthma, chronic obstructive pulmonary disease, lung cancer, bronchiectasis, pneumonia, breathing pattern disorder, and interstitial lung disease as well as volunteers with no history of lung disease will be asked to breathe into the Inflammacheck device to record their breath sample. Results The results from this study will be available in 2022, in anticipation of COVID-19–related delays. Conclusions This study will investigate the EBC H2O2, as well as other exhaled breath parameters, for use as a future diagnostic tool.


2020 ◽  
Author(s):  
Lauren Fox ◽  
Jessica Gates ◽  
Ruth De Vos ◽  
Laura Wiffen ◽  
Alexander Hicks ◽  
...  

BACKGROUND More than 7% of the world’s population is living with a chronic respiratory condition. In the United Kingdom, lung disease affects approximately 1 in 5 people, resulting in over 700,000 hospital admissions each year. People with respiratory conditions have several symptoms and can require multiple health care visits and investigations before a diagnosis is made. The tests available can be difficult to perform, especially if a person is symptomatic, leading to poor quality results. A new, easy-to-perform, point-of-care test that can be performed in any health care setting and that can differentiate between various respiratory conditions would have a significant, beneficial impact on the ability to diagnose respiratory diseases. OBJECTIVE The objective of this study is to use a new handheld device (Inflammacheck) in different respiratory conditions to measure the exhaled breath condensate hydrogen peroxide (EBC H<sub>2</sub>O<sub>2</sub>) and compare these results with those of healthy controls and with each other. This study also aims to determine whether the device can measure other parameters, including breath humidity, breath temperature, breath flow dynamics, and end tidal carbon dioxide. METHODS We will perform a single-visit, cross-sectional observational study of EBC H<sub>2</sub>O<sub>2</sub> levels, as measured by Inflammacheck, in people with respiratory disease and volunteers with no known lung disease. Participants with a confirmed diagnosis of asthma, chronic obstructive pulmonary disease, lung cancer, bronchiectasis, pneumonia, breathing pattern disorder, and interstitial lung disease as well as volunteers with no history of lung disease will be asked to breathe into the Inflammacheck device to record their breath sample. RESULTS The results from this study will be available in 2022, in anticipation of COVID-19–related delays. CONCLUSIONS This study will investigate the EBC H<sub>2</sub>O<sub>2</sub>, as well as other exhaled breath parameters, for use as a future diagnostic tool.


2007 ◽  
Vol 148 (26) ◽  
pp. 1217-1224 ◽  
Author(s):  
Balázs Szili ◽  
András Bikov ◽  
Márk Kollai ◽  
Ildikó Horváth

A kilélegzett levegő kondenzálása és a kondenzátum (EBC: Exhaled Breath Condensate) vizsgálata napjainkra egyre szélesebb körben terjed el pulmonológiai kutatásokban. Az eljárás során nem invazív úton nyerhetünk mintát a légutakból úgy, hogy a kilélegzett gázkeveréket egy hűtött kamrán áramoltatjuk át, és a kamra falára lecsapódó párát vizsgáljuk. A minta számos különböző mediátort, biomarkert tartalmaz. Kiemelt jelentőségű a különböző, eddig vizsgált biomarkerek közül a pH. Mérése egyszerű, olcsó és az optimális mérési tartományon belül van. Problémát a pH-érték instabilitása jelent, amit főként a minta CO 2 -koncentrációjának változása okoz. Számos publikáció jelent meg, amelyekben különböző légúti megbetegedésekben vizsgálták a kondenzátum pH-ját. Asthma bronchialéban (különösen akut exacerbatióban), valamint krónikus obstruktív tüdőbetegségben (COPD) savasabbnak találták a kondenzátumot. Szteroidkezelés hatására mindkét betegségben emelkedik a pH. Bronchiectasiában, cisztikus fibrosisban, valamint krónikus köhögésben (asthma bronchiale, gastrooesophagealis reflux, rhinitis chronica, ismeretlen eredet) is savasabbnak találták az EBC-mintákat. A légutak savasodása a különböző kórállapotokban fontos szerepet játszhat a betegségek patomechanizmusában, és az ezt jelző EBC-pH szerepet kaphat a légúti megbetegedések követésében.


2017 ◽  
Vol 53 (3) ◽  
pp. 120-127
Author(s):  
Alfredo Guillen-del Castillo ◽  
Sara Sánchez-Vidaurre ◽  
Carmen P. Simeón-Aznar ◽  
María J. Cruz ◽  
Vicente Fonollosa-Pla ◽  
...  

2010 ◽  
Vol 21 (1-Part-II) ◽  
pp. e235-e244 ◽  
Author(s):  
Philippe P. R. Rosias ◽  
Charlotte M. Robroeks ◽  
Kim D. van de Kant ◽  
Ger T. Rijkers ◽  
Luc J. Zimmermann ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document